KRP-213
IgA Nephropathy
PreclinicalActive
Key Facts
About Kissei Pharmaceutical
Kissei Pharmaceutical's mission is to contribute to global healthcare by developing and providing innovative, high-quality pharmaceutical products. The company has achieved a strong market position in Japan through its established expertise in urology and nephrology, supported by a portfolio of marketed products and a promising late-stage pipeline. Its strategy centers on deepening its specialization in core therapeutic areas while expanding its global footprint through strategic in-licensing and co-development partnerships. With a market capitalization of approximately $193.58 billion, Kissei possesses the financial strength to advance its R&D ambitions and pursue strategic opportunities.
View full company profileTherapeutic Areas
Other IgA Nephropathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Narsoplimab | Omeros | Phase 3 |